Wedbush Analysts Reduce Earnings Estimates for Pharvaris (NASDAQ:PHVS)

Pharvaris (NASDAQ:PHVS) – Equities research analysts at Wedbush reduced their Q3 2024 earnings estimates for Pharvaris in a research note issued to investors on Thursday, August 15th. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.61) per share for the quarter, down from their prior forecast of ($0.47). Wedbush currently has a “Outperform” rating and a $31.00 target price on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.39) per share. Wedbush also issued estimates for Pharvaris’ Q4 2024 earnings at ($0.64) EPS, FY2024 earnings at ($2.43) EPS, FY2025 earnings at ($2.98) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($1.91) EPS and FY2028 earnings at $1.01 EPS.

Other analysts also recently issued reports about the company. Morgan Stanley restated an “overweight” rating and issued a $34.00 price target on shares of Pharvaris in a research note on Monday, April 22nd. Oppenheimer raised their target price on Pharvaris from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Wednesday, July 3rd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.80.

Pharvaris Trading Down 0.3 %

NASDAQ PHVS opened at $18.70 on Monday. The business’s 50 day moving average is $17.82 and its two-hundred day moving average is $21.21. Pharvaris has a 12-month low of $15.00 and a 12-month high of $33.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PHVS. venBio Partners LLC raised its position in shares of Pharvaris by 15.4% during the 4th quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after purchasing an additional 654,832 shares during the last quarter. Deerfield Management Company L.P. Series C increased its position in Pharvaris by 31.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after buying an additional 335,687 shares in the last quarter. Commodore Capital LP acquired a new position in shares of Pharvaris in the fourth quarter worth $22,440,000. Sofinnova Investments Inc. lifted its position in shares of Pharvaris by 2.9% in the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock valued at $11,309,000 after acquiring an additional 16,862 shares in the last quarter. Finally, Vivo Capital LLC purchased a new stake in shares of Pharvaris in the fourth quarter valued at $7,994,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.